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 Figure S1. A mixture of α and β isomer of complex 2a evidenced in the 1H NMR spectrum. 
Figure S2. Three crystallographically independent molecules of complex 6a. Thermal ellipsoids 
are shown at 30% probability level and hydrogen atoms are omitted for better clarity of 
presentation.
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Figure S3. Stability of complexes 1b and 4a in dmso solution over a period of 7 days followed by 1H NMR spectroscopy. Spectra were 
taken 1) immediately, 2) after 1 day, 3) after 2 days, 4) after 3 days and d) after a week indicating that no degradation of complexes was 
observed.
Figure S4: Reactivity of complex 1a towards GMP in dmso-d6/D2O 9:1.
Figure S5: Reactivity of complex 1b towards GMP in dmso-d6/D2O 9:1.
Figure S6. Visual appearance of 8a and 8b in comparison to 7a showing bright orange color of 
these two complexes in comparison to yellow or pale yellow of all other complexes.
Figure S7. Cellular DNA degradation in A) carcinoma A549 cells and B) zebrafish embryos, 
induced by complexes 1a, 1b, 3a, 3b, 5a and 5b in comparison to cisplatin (Cis) and dmso treated 
cells. DNA molecular weight marker in lane M (1 kb ladder, Nippon Genetics).
Table S1: Compound nomenclature according to IUPAC recommendations.*
Cpd Isomer IUPAC Cpd Isomer IUPAC
1a-7a α SP-4-4 1b-7b α SP-4-4
β SP-4-3 β SP-4-3
8a α SP-4-3 8b α SP-4-4
β SP-4-4 β SP-4-2
* In Nomenclature of Inorganic Chemistry, IUPAC Recommendations, ed. N. G. Connelly, T. 
Damhus, R. M. Hartshorn, A. T. Hutton, Royal Society of Chemistry, Cambridge, 2005, IR-
9.3, 180.
Table S2. Crystallographic data for compounds β-1b, α-2a, and β-2a.
Compound β-1b α-2a·CH2Cl2* β-2a*
Empirical formula C15H16Cl2IN4OPPt C12H13Cl3N2O4PtS C11H11ClN2O4PtS
Mw 692.18 582.74 497.82
T, K 150(2) 150(2) 150(2)
Crystal system Triclinic Monoclinic Monoclinic
Space group P -1 C 2/c P 21/m
a, Å 5.810(5) 19.3571(7) A 9.4359(6)
b, Å 12.770(5) 6.8349(3) 6.7378(4)
c, Å 12.865(5) 25.1990(10) 10.5414(5)
α, deg. 84.543(5) 90 90
β, deg. 81.308(5) 95.245(4) 97.352(5)
γ, deg. 78.412(5) 90 90
V, Å3 922.2(9) 3320.0(2) 664.68(7)
Z 2 8 2
Dcalc, g/cm3 2.493 2.332 2.487
µ, mm-1 9.670 9.080 10.926
F(000) 644 2208 468
Crystal size, mm 0.2×0.15×0.10 0.25×0.25×0.20 0.15×0.05×0.05
Color yellow orange yellow
Data collected / unique 7153 / 4237 7110 / 3800 3476 / 1655
Rint 0.0271 0.0250 0.0326
Restraints / parameters 0 / 226 0 / 208 0 / 118
S 1.022 1.047 1.103
R1, wR2 [I>2σ(I)] 0.0288 / 0.0544 0.0248 / 0.0506 0.0384 / 0.0814
R1, wR2 (all data) 0.0348 / 0.0580 0.0295 / 0.0527 0.0429 / 0.0833
Larg. diff. peak/hole (e·Å–3) 1.452 / -1.359 0.705 / -1.125 5.411 / -2.641
* for α/β notations see Table 1.
Table S3. Crystallographic data for compounds β-4b and β-6a.
Compound β-4b (3·β-6a)·acetone
Empirical formula C15H16ClI2N4OPPt C39H42Cl9N3O7Pt3S3
Mw 783.63 1665.25
T, K 150(2) 150(2)
Crystal system Triclinic Monoclinic
Space group P -1 P 21/c
a, Å 5.8236(3) 23.9829(5)
b, Å 9.9683(6) 10.1789(3)
c, Å 17.4696(9) 20.8153(5)
α, deg. 86.328(4) 90
β, deg. 88.630(4) 103.822(2)
γ, deg. 73.328(5) 90
V, Å3 969.49(9) 4934.3(2)
Z 2 4
Dcalc, g/cm3 2.684 2.242
µ, mm-1 10.653 9.149
F(000) 716 3152
Crystal size, mm 0.15×0.05×0.05 0.15×0.05×0.05
Color yellow yellow
Data collected / unique 7583 / 4435 36804 / 11011
Rint 0.0323 0.0403
Restraints / parameters 0 / 226 0 / 588
S 1.011 0.983
R1, wR2 [I>2σ(I)] 0.0327 / 0.0599 0.0247 / 0.0423
R1, wR2 (all data) 0.0422 / 0.0652 0.0358 / 0.0448
Larg. diff. peak/hole (e·Å–3) 2.258 / -1.579 0.973 / -1.111
* for α/β notations see Table 1.
Table S4. Instrument operating conditions for ICP-QMS
Rf power (W) 1548
Gas flows (L/min) 13.9; 1.09; 0.8
Acquisition time 3 x 50s
Points per peak 3
Dwell time (ns) 10
Detector mode Pulse
Measured isotopes 194Pt
Table S5. Lethal and teratogenic effects observed in zebrafish (Danio rerio) embryos at different 
hours post fertilization (hpf). 
Category Developmental endpoints Exposure time (hpf)
24 48 72 96 
Lethal effect Egg coagulationa ● ● ● ●
No somite formation ● ● ● ●
Tail not detached ● ● ● ●
No heart-beat ● ● ●
Teratogenic effect Malformation of head ● ● ● ●
Malformation of eyesb ● ● ● ●
Malformation of sacculi/otolithsc ● ● ● ●
Malformation of chorda ● ● ● ●
Malformation of taild ● ● ● ●
Scoliosis ● ● ● ●
Heart beat frequency ● ● ●
Blood circulation ● ● ●
Pericardial edema ● ● ● ●
Yolk edema ● ● ● ●
Yolk deformation ● ● ● ●
Growth retardatione ● ● ● ●
a No clear organs structure are recognized
b Malformation of eyes was recorded for the retardation in eye development and abnormality in shape and size.
c Presence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths and/or 
sacculi (otic vesicles).
d Tail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed by 
optical comparation.
e Growth retardation was recorded by comparing with the control embryos in development or size (before hatching, at 
24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical comparation using a 
inverted microscope (CKX41; Olympus, Tokyo, Japan).
